GARP Monoclonal Antibody (G14D9), FITC, eBioscience™, Invitrogen™

Description

Description: The G14D9 monoclonal antibody reacts with human Glycoprotein A Repetitions Predominant (GARP, also known as LRRC32 or Garpin). GARP is an approximately 80 kDa glycoprotein that is expressed on the cell surface. Using northern blot, RT-PCR or microarray analyses, the expression of GARP has been reported in placenta, lung, kidney, heart, ovary, liver, skeletal muscle, and pancreas. Protein expression has been observed on megakaryocytes, platelets and activated regulatory T (Treg) cells. The expression of GARP on the surface of activated Treg cells has been reported to be necessary for their suppressive function, possibly related to its role as a cell surface receptor for LAP/TGF beta. Applications Reported: This G14D9 antibody has been reported for use in flow cytometric analysis. Applications Tested: This G14D9 antibody has been pre-titrated and tested by flow cytometric analysis of stimulated human peripheral blood cells. This can be used at 5 μL (0.5 μg) per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser. Filtration: 0.2 μm post-manufacturing filtered.

GARP, also known as leucine rich repeat containing 32, is a type I membrane protein with twenty-two leucine-rich repeats and a short intracytoplasmic region. GARP was identified based on the analysis of gene expression profiling of Treg and Th cells following TCR stimulation. Since GARP is expressed in CD4+, CD25+, FoxP3+ cells (Tregs), it may be a candidate for cell surface marker for Treg cells.